Page last updated: 2024-11-05

2,5-dimethylfuran

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,5-dimethylfuran is a heterocyclic organic compound with the formula C6H8O. It is a colorless liquid with a sweet, pungent odor. It is a potential biofuel, with a high energy density and low carbon footprint. The compound has been studied as a potential fuel additive and a replacement for gasoline. 2,5-dimethylfuran can be synthesized from biomass sources such as lignocellulosic biomass. It can also be synthesized from furfural, which is a derivative of plant sugars. 2,5-dimethylfuran has a high flash point and is relatively stable in the presence of air and water. Its high energy density and low carbon footprint make it a promising candidate for replacing gasoline as a fuel. Further research is needed to optimize its production and to develop technologies for its widespread use.'

2,5-dimethylfuran: metabolite of n-hexane [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2,5-dimethylfuran : A member of the class of furans that is furan in which the hydrogens at positions 2 and 5 are replaced by methyl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID12266
CHEMBL ID1416448
CHEBI ID89052
MeSH IDM0113566

Synonyms (50)

Synonym
dr5hl9oj7y ,
unii-dr5hl9oj7y
625-86-5
nsc6220
wln: t5oj b1 e1
nsc-6220
2,5-dimethylfuran
furan, 2,5-dimethyl-
NCGC00091694-01
ccris 3158
einecs 210-914-3
ai3-21212
nsc 6220
inchi=1/c6h8o/c1-5-3-4-6(2)7-5/h3-4h,1-2h
2,5-dimethylfuran, 99%
D0725
FT-0667445
FT-0655041
AKOS000120051
2,5-dimethyl-furan
tox21_202472
NCGC00260021-01
cas-625-86-5
dtxsid7022093 ,
dtxcid102093
FT-0610466
2,5-dimethylfuran [mi]
dimethylfuran, 2,5-
fema no. 4106
2,5-dimethylfuran [fhfi]
2,5-dimethyl furan
AM81813
2,5-dimethylfurane
CHEMBL1416448
chebi:89052 ,
STR09233
Q-100722
PS-9347
mfcd00003250
F0001-1679
2,5-dimethylfuran, >=99%
2,5-dimetylfuran
121571-93-5
2,5-dimethylfuran-d6
F16580
Q209267
2,5-dimethylfuran; 2-methyl-5-methylfuran; nsc 6220
2,5-dimethylfuran 1000 microg/ml in acetonitrile
2,5-dimethylfuran 100 microg/ml in acetonitrile
EN300-19818
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
human urinary metaboliteAny metabolite (endogenous or exogenous) found in human urine samples.
antifungal agentAn antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
fumigantA volatile or volatilizable chemical compound utilized for control of pests in buildings, soil, grain, as well as during processing of goods to be imported or exported to prevent transfer of exotic organisms.
fuelAn energy-rich substance that can be transformed with release of usable energy.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
Maillard reaction productAny thermal degradation product obtained as a result of a chemical reaction between an amino acid and a reducing sugar (Maillard reaction, a non-enzymatic browning procedure that usually imparts flavour to starch-based food products).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
furansCompounds containing at least one furan ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency63.09570.004023.8416100.0000AID485290
interleukin 8Homo sapiens (human)Potency59.55720.047349.480674.9780AID651758
retinoid X nuclear receptor alphaHomo sapiens (human)Potency0.00310.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency61.62820.001530.607315,848.9004AID1224841
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency0.12400.001024.504861.6448AID743212
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (74)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (5.41)18.7374
1990's6 (8.11)18.2507
2000's11 (14.86)29.6817
2010's42 (56.76)24.3611
2020's11 (14.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.08 (24.57)
Research Supply Index4.32 (2.92)
Research Growth Index5.16 (4.65)
Search Engine Demand Index50.49 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (5.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other70 (94.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]